Certain Warrants of HeartBeam, Inc. are subject to a Lock-Up Agreement Ending on 31-OCT-2023.
October 30, 2023
Share
Certain Warrants of HeartBeam, Inc. are subject to a Lock-Up Agreement Ending on 31-OCT-2023. These Warrants will be under lockup for 181 days starting from 3-MAY-2023 to 31-OCT-2023.
Details:
Officers and directors have agreed to be subject to a lock -up period of 180 days following the closing of this offering. This means that, during the applicable lock -up period, those persons may not offer for sale, contract to sell, sell, distribute, grant any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose of, directly or indirectly, any shares of common stock or any securities convertible into, or exercisable or exchangeable for, shares of common stock.
HeartBeam, Inc. is a cardiac technology company. The Company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. The Company is engaged in the development of its proprietary and patented Vector Electrocardiography (VECG) technology platform. Its VECG is capable of developing three-dimensional vector images of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It has two patented products in development, such as HeartBeam AIMI and HeartBeam AIMIGo. HeartBeam AIMI is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack. HeartBeam AIMIGo is a credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms.
HEARTBEAM, INC. 
